NASDAQ$CRDF
Cardiff Oncology Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Announced second quarter 2020 results and company highlights.
Cardiff Oncology reported its second quarter 2020 results, highlighting clinical advancements in KRAS-mutated metastatic colorectal cancer and acute myeloid leukemia programs, along with securing $25.1 million in equity investments, warrant exercises, and clinical trial funding commitments.
- Presented data demonstrating efficacy of onvansertib in combination with standard-of-care therapy in KRAS-mutated metastatic colorectal cancer.
- Announced positive efficacy and safety results of Phase 1b trial in relapsed/refractory acute myeloid leukemia.
- Advanced Phase 2 trial in metastatic castrate-resistant prostate cancer.
- Secured financing of $25 million from equity investments, warrant exercises, and clinical study commitments.
Headline financials
Revenue & EPS history
Cardiff Oncology · Revenue · Quarterly
$42.6K
Revenue by segment
Cardiff Oncology · $41K total across 1 segment · Q1 2026
- Royalties$41K—100.0%
Forward guidance
Cardiff Oncology did not provide specific forward guidance in this earnings report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
+2.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+2.8%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+118.2%
Q4 2010
Best reaction
-21.2%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +3.6% | -8.3% | |
| Q4 2025 | +12.9% | +14.1% | -8.8% | |
| Q3 2025 | -3.1% | -0.4% | -6.2% | |
| Q2 2025 | -1.3% | -24.2% | -36.6% | |
| Q1 2025 | +4.0% | +2.5% | +37.4% | |
| Q4 2024 | +4.4% | +5.2% | -19.0% | |
| Q3 2024 | -19.2% | -17.6% | -39.4% | |
| Q2 2024 | +11.2% | +5.1% | -1.4% | |
| Q1 2024 | -16.8% | -21.7% | -24.8% | |
| Q4 2023 | +59.9% | +100.5% | +193.4% | |
| Q3 2023 | +5.7% | +3.8% | +20.0% | |
| Q2 2023 | -5.0% | -8.3% | -15.6% | |
| Q1 2023 | +1.1% | -4.8% | -12.4% | |
| Q4 2022 | +2.3% | +7.6% | -4.1% | |
| Q3 2022 | -4.7% | -10.7% | +5.4% | |
| Q2 2022 | +15.0% | +30.0% | +27.7% | |
| Q1 2022 | -7.7% | -11.9% | -0.7% | |
| Q4 2021 | +7.1% | +0.4% | -5.6% | |
| Q3 2021 | -5.1% | -3.6% | -14.1% | |
| Q2 2021 | +15.0% | +19.4% | +51.3% | |
| Q1 2021 | -5.5% | -13.1% | -24.5% | |
| Q4 2020 | +0.6% | +8.0% | -3.1% | |
| Q3 2020 | +10.6% | +5.8% | +26.6% | |
| Q2 2020 | -14.6% | -10.2% | -3.4% | |
| Q1 2020 | +0.8% | +6.7% | +167.5% | |
| Q4 2019 | -2.8% | +12.8% | -24.1% | |
| Q3 2019 | +1.8% | +2.4% | -20.8% | |
| Q2 2019 | -4.1% | -10.0% | +10.6% | |
| Q1 2019 | -8.1% | -11.2% | -11.2% | |
| Q4 2018 | +25.2% | +47.0% | +18.2% | |
| Q3 2018 | +6.7% | +4.0% | -6.7% | |
| Q2 2018 | -1.2% | -1.2% | +0.0% | |
| Q1 2018 | +0.0% | -3.6% | -47.3% | |
| Q4 2017 | -6.2% | -3.1% | +6.2% | |
| Q3 2017 | -1.5% | -4.4% | -26.5% | |
| Q2 2017 | -7.1% | +1.2% | -13.1% | |
| Q1 2017 | -5.0% | -1.2% | +1.3% | |
| Q4 2016 | -21.2% | -28.5% | -37.0% | |
| Q3 2016 | -5.6% | -15.5% | -29.6% | |
| Q2 2016 | -6.6% | -0.4% | -11.0% | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -18.7% | — | — | |
| Q3 2015 | +11.7% | — | — | |
| Q2 2015 | -15.0% | — | — | |
| Q1 2015 | +9.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q4 2013 | +7.9% | — | — | |
| Q3 2013 | +12.2% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q4 2012 | -2.4% | — | — | |
| Q1 2013 | -2.4% | — | — | |
| Q3 2012 | +2.3% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | +8.8% | — | — | |
| Q4 2011 | -3.9% | — | — | |
| Q3 2011 | -17.1% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +118.2% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +13.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro